JavaScript NENÍ povolen !

Prosím povolte JavaScript.

* Zobrazit nápovědu

Reset

Autor: Brunner-La Rocca, Hans-Peter

3 záznamů v Medvik Filtry

Článek

Empagliflozin in Heart Failure with a Preserved Ejection Fraction

Anker, Stefan D
Autor Anker, Stefan D From the Department of Cardiology (CVK) and the Berlin Institute of Health Center for Regenerative Therapies (BCRT), German Center for Cardiovascular Research (DZHK) partner site Berlin, Charité Universitätsmedizin Berlin, Berlin (S.D.A.), Universitätsklinikum des Saarlandes, Homberg (M. Böhm), RWTH Aachen University, Aachen (N.M.), Boehringer Ingelheim Pharma, Biberach (C.Z., S.S.), Boehringer Ingelheim International, Ingelheim (W.J., M. Brueckmann), and the Faculty of Medicine Mannheim, University of Heidelberg, Mannheim (M. Brueckmann) - all in Germany the University of Mississippi Medical Center, Jackson (J.B.) National and Kapodistrian University of Athens School of Medicine, Athens (G.F.) Université de Lorraine, INSERM, Centre d'Investigations Cliniques Plurithématique 1433, and INSERM Unité 1116, CHRU, F-CRIN INI-CRCT (Cardiovascular and Renal Clinical Trialists) (J.P.F.), and Université de Lorraine, INSERM INI-CRCT, CHRU (F.Z.) - both in Nancy, France the Cardiovascular Research and Development Center, Department of Surgery and Physiology, Faculty of Medicine of the University of Porto, Porto, Portugal (J.P.F.) Unidade de Insuficiência Cardíaca, Instituto do Coracao, Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de São Paulo, São Paulo (E.B.) Maastricht University Medical Center and the School for Cardiovascular Disease CARIM - both in Maastricht, the Netherlands (H.-P.B.-L.R.) the Department of Medicine, Seoul National University Bundang Hospital, Seoul, South Korea (D.-J.C.) Max Superspeciality Hospital, Saket, New Delhi, India (V.C.) the National Institute of Cardiology, Mexico City (E.C.-V.) McGill University Health Centre, Montreal (N.G.), and St. Michael's Hospital, University of Toronto, Toronto (S.V.) - both in Canada the Cardiology Service, Fundación Valle del Lili, Universidad Icesi, Cali, Colombia (J.E.G.-M.) the Department of Cardiovascular Diseases, University Hospitals Leuven, Leuven, Belgium (S.J.) Massachusetts General Hospital and Baim Institute for Clinical Research, Boston (J.L.J.) University Hospital, Santiago de Compostela, Spain (J.R.G.-J.) Heart and Vascular Center, Semmelweiss University, Budapest, Hungary (B.M.) Victorian Heart Institute, Monash University, Melbourne, VIC, Australia (S.J.N.) Argentine Catholic University, and Medical Advisor in Heart Failure, Pulmonary Hypertension and Intrathoracic Transplant at FLENI and IADT Institute - both in Buenos Aires (S.V.P.) Central Michigan University, Mount Pleasant (I.L.P.) Wroclaw Medical University, Wroclaw, Poland (P.P.) the Cardiovascular Department, Cardiology Division, Papa Giovanni XXIII Hospital, Bergamo (M.S.), and Università di Pisa, Pisa (S.T.) - both in Italy National Heart Centre Singapore, Singapore (D.S.) the Internal Cardiology Department, St. Ann University Hospital and Masaryk University, Brno, Czech Republic (J.S.) the University of Leicester, Glenfield General Hospital, Leicester (I.S.), the University of Glasgow, Glasgow (N.S.), the London School of Hygiene and Tropical Medicine (S.J.P.), and Imperial College, London (M.P.) - all in the United Kingdom Kyushu University, Fukuoka, Japan (H.T.) the University of Medicine and Pharmacy, Carol Davila University and Emergency Hospital, Bucharest, Romania (D.V.) the Heart Failure Center, Fuwai Hospital, Chinese Academy of Medical Science and Peking Union Medical College, Beijing (J.Z.) the Veterans Affairs Medical Center, Washington, DC (P.C.) National Heart Centre Singapore, Duke-National University of Singapore, Singapore (C.S.P.L.) Boehringer Ingelheim Pharmaceuticals, Ridgefield, CT (J.M.S.) and Baylor Heart and Vascular Institute, Dallas (M.P.)
Butler, Javed
Autor Butler, Javed From the Department of Cardiology (CVK) and the Berlin Institute of Health Center for Regenerative Therapies (BCRT), German Center for Cardiovascular Research (DZHK) partner site Berlin, Charité Universitätsmedizin Berlin, Berlin (S.D.A.), Universitätsklinikum des Saarlandes, Homberg (M. Böhm), RWTH Aachen University, Aachen (N.M.), Boehringer Ingelheim Pharma, Biberach (C.Z., S.S.), Boehringer Ingelheim International, Ingelheim (W.J., M. Brueckmann), and the Faculty of Medicine Mannheim, University of Heidelberg, Mannheim (M. Brueckmann) - all in Germany the University of Mississippi Medical Center, Jackson (J.B.) National and Kapodistrian University of Athens School of Medicine, Athens (G.F.) Université de Lorraine, INSERM, Centre d'Investigations Cliniques Plurithématique 1433, and INSERM Unité 1116, CHRU, F-CRIN INI-CRCT (Cardiovascular and Renal Clinical Trialists) (J.P.F.), and Université de Lorraine, INSERM INI-CRCT, CHRU (F.Z.) - both in Nancy, France the Cardiovascular Research and Development Center, Department of Surgery and Physiology, Faculty of Medicine of the University of Porto, Porto, Portugal (J.P.F.) Unidade de Insuficiência Cardíaca, Instituto do Coracao, Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de São Paulo, São Paulo (E.B.) Maastricht University Medical Center and the School for Cardiovascular Disease CARIM - both in Maastricht, the Netherlands (H.-P.B.-L.R.) the Department of Medicine, Seoul National University Bundang Hospital, Seoul, South Korea (D.-J.C.) Max Superspeciality Hospital, Saket, New Delhi, India (V.C.) the National Institute of Cardiology, Mexico City (E.C.-V.) McGill University Health Centre, Montreal (N.G.), and St. Michael's Hospital, University of Toronto, Toronto (S.V.) - both in Canada the Cardiology Service, Fundación Valle del Lili, Universidad Icesi, Cali, Colombia (J.E.G.-M.) the Department of Cardiovascular Diseases, University Hospitals Leuven, Leuven, Belgium (S.J.) Massachusetts General Hospital and Baim Institute for Clinical Research, Boston (J.L.J.) University Hospital, Santiago de Compostela, Spain (J.R.G.-J.) Heart and Vascular Center, Semmelweiss University, Budapest, Hungary (B.M.) Victorian Heart Institute, Monash University, Melbourne, VIC, Australia (S.J.N.) Argentine Catholic University, and Medical Advisor in Heart Failure, Pulmonary Hypertension and Intrathoracic Transplant at FLENI and IADT Institute - both in Buenos Aires (S.V.P.) Central Michigan University, Mount Pleasant (I.L.P.) Wroclaw Medical University, Wroclaw, Poland (P.P.) the Cardiovascular Department, Cardiology Division, Papa Giovanni XXIII Hospital, Bergamo (M.S.), and Università di Pisa, Pisa (S.T.) - both in Italy National Heart Centre Singapore, Singapore (D.S.) the Internal Cardiology Department, St. Ann University Hospital and Masaryk University, Brno, Czech Republic (J.S.) the University of Leicester, Glenfield General Hospital, Leicester (I.S.), the University of Glasgow, Glasgow (N.S.), the London School of Hygiene and Tropical Medicine (S.J.P.), and Imperial College, London (M.P.) - all in the United Kingdom Kyushu University, Fukuoka, Japan (H.T.) the University of Medicine and Pharmacy, Carol Davila University and Emergency Hospital, Bucharest, Romania (D.V.) the Heart Failure Center, Fuwai Hospital, Chinese Academy of Medical Science and Peking Union Medical College, Beijing (J.Z.) the Veterans Affairs Medical Center, Washington, DC (P.C.) National Heart Centre Singapore, Duke-National University of Singapore, Singapore (C.S.P.L.) Boehringer Ingelheim Pharmaceuticals, Ridgefield, CT (J.M.S.) and Baylor Heart and Vascular Institute, Dallas (M.P.)
Filippatos, Gerasimos
Autor Filippatos, Gerasimos From the Department of Cardiology (CVK) and the Berlin Institute of Health Center for Regenerative Therapies (BCRT), German Center for Cardiovascular Research (DZHK) partner site Berlin, Charité Universitätsmedizin Berlin, Berlin (S.D.A.), Universitätsklinikum des Saarlandes, Homberg (M. Böhm), RWTH Aachen University, Aachen (N.M.), Boehringer Ingelheim Pharma, Biberach (C.Z., S.S.), Boehringer Ingelheim International, Ingelheim (W.J., M. Brueckmann), and the Faculty of Medicine Mannheim, University of Heidelberg, Mannheim (M. Brueckmann) - all in Germany the University of Mississippi Medical Center, Jackson (J.B.) National and Kapodistrian University of Athens School of Medicine, Athens (G.F.) Université de Lorraine, INSERM, Centre d'Investigations Cliniques Plurithématique 1433, and INSERM Unité 1116, CHRU, F-CRIN INI-CRCT (Cardiovascular and Renal Clinical Trialists) (J.P.F.), and Université de Lorraine, INSERM INI-CRCT, CHRU (F.Z.) - both in Nancy, France the Cardiovascular Research and Development Center, Department of Surgery and Physiology, Faculty of Medicine of the University of Porto, Porto, Portugal (J.P.F.) Unidade de Insuficiência Cardíaca, Instituto do Coracao, Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de São Paulo, São Paulo (E.B.) Maastricht University Medical Center and the School for Cardiovascular Disease CARIM - both in Maastricht, the Netherlands (H.-P.B.-L.R.) the Department of Medicine, Seoul National University Bundang Hospital, Seoul, South Korea (D.-J.C.) Max Superspeciality Hospital, Saket, New Delhi, India (V.C.) the National Institute of Cardiology, Mexico City (E.C.-V.) McGill University Health Centre, Montreal (N.G.), and St. Michael's Hospital, University of Toronto, Toronto (S.V.) - both in Canada the Cardiology Service, Fundación Valle del Lili, Universidad Icesi, Cali, Colombia (J.E.G.-M.) the Department of Cardiovascular Diseases, University Hospitals Leuven, Leuven, Belgium (S.J.) Massachusetts General Hospital and Baim Institute for Clinical Research, Boston (J.L.J.) University Hospital, Santiago de Compostela, Spain (J.R.G.-J.) Heart and Vascular Center, Semmelweiss University, Budapest, Hungary (B.M.) Victorian Heart Institute, Monash University, Melbourne, VIC, Australia (S.J.N.) Argentine Catholic University, and Medical Advisor in Heart Failure, Pulmonary Hypertension and Intrathoracic Transplant at FLENI and IADT Institute - both in Buenos Aires (S.V.P.) Central Michigan University, Mount Pleasant (I.L.P.) Wroclaw Medical University, Wroclaw, Poland (P.P.) the Cardiovascular Department, Cardiology Division, Papa Giovanni XXIII Hospital, Bergamo (M.S.), and Università di Pisa, Pisa (S.T.) - both in Italy National Heart Centre Singapore, Singapore (D.S.) the Internal Cardiology Department, St. Ann University Hospital and Masaryk University, Brno, Czech Republic (J.S.) the University of Leicester, Glenfield General Hospital, Leicester (I.S.), the University of Glasgow, Glasgow (N.S.), the London School of Hygiene and Tropical Medicine (S.J.P.), and Imperial College, London (M.P.) - all in the United Kingdom Kyushu University, Fukuoka, Japan (H.T.) the University of Medicine and Pharmacy, Carol Davila University and Emergency Hospital, Bucharest, Romania (D.V.) the Heart Failure Center, Fuwai Hospital, Chinese Academy of Medical Science and Peking Union Medical College, Beijing (J.Z.) the Veterans Affairs Medical Center, Washington, DC (P.C.) National Heart Centre Singapore, Duke-National University of Singapore, Singapore (C.S.P.L.) Boehringer Ingelheim Pharmaceuticals, Ridgefield, CT (J.M.S.) and Baylor Heart and Vascular Institute, Dallas (M.P.)
Ferreira, João P
Autor Ferreira, João P From the Department of Cardiology (CVK) and the Berlin Institute of Health Center for Regenerative Therapies (BCRT), German Center for Cardiovascular Research (DZHK) partner site Berlin, Charité Universitätsmedizin Berlin, Berlin (S.D.A.), Universitätsklinikum des Saarlandes, Homberg (M. Böhm), RWTH Aachen University, Aachen (N.M.), Boehringer Ingelheim Pharma, Biberach (C.Z., S.S.), Boehringer Ingelheim International, Ingelheim (W.J., M. Brueckmann), and the Faculty of Medicine Mannheim, University of Heidelberg, Mannheim (M. Brueckmann) - all in Germany the University of Mississippi Medical Center, Jackson (J.B.) National and Kapodistrian University of Athens School of Medicine, Athens (G.F.) Université de Lorraine, INSERM, Centre d'Investigations Cliniques Plurithématique 1433, and INSERM Unité 1116, CHRU, F-CRIN INI-CRCT (Cardiovascular and Renal Clinical Trialists) (J.P.F.), and Université de Lorraine, INSERM INI-CRCT, CHRU (F.Z.) - both in Nancy, France the Cardiovascular Research and Development Center, Department of Surgery and Physiology, Faculty of Medicine of the University of Porto, Porto, Portugal (J.P.F.) Unidade de Insuficiência Cardíaca, Instituto do Coracao, Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de São Paulo, São Paulo (E.B.) Maastricht University Medical Center and the School for Cardiovascular Disease CARIM - both in Maastricht, the Netherlands (H.-P.B.-L.R.) the Department of Medicine, Seoul National University Bundang Hospital, Seoul, South Korea (D.-J.C.) Max Superspeciality Hospital, Saket, New Delhi, India (V.C.) the National Institute of Cardiology, Mexico City (E.C.-V.) McGill University Health Centre, Montreal (N.G.), and St. Michael's Hospital, University of Toronto, Toronto (S.V.) - both in Canada the Cardiology Service, Fundación Valle del Lili, Universidad Icesi, Cali, Colombia (J.E.G.-M.) the Department of Cardiovascular Diseases, University Hospitals Leuven, Leuven, Belgium (S.J.) Massachusetts General Hospital and Baim Institute for Clinical Research, Boston (J.L.J.) University Hospital, Santiago de Compostela, Spain (J.R.G.-J.) Heart and Vascular Center, Semmelweiss University, Budapest, Hungary (B.M.) Victorian Heart Institute, Monash University, Melbourne, VIC, Australia (S.J.N.) Argentine Catholic University, and Medical Advisor in Heart Failure, Pulmonary Hypertension and Intrathoracic Transplant at FLENI and IADT Institute - both in Buenos Aires (S.V.P.) Central Michigan University, Mount Pleasant (I.L.P.) Wroclaw Medical University, Wroclaw, Poland (P.P.) the Cardiovascular Department, Cardiology Division, Papa Giovanni XXIII Hospital, Bergamo (M.S.), and Università di Pisa, Pisa (S.T.) - both in Italy National Heart Centre Singapore, Singapore (D.S.) the Internal Cardiology Department, St. Ann University Hospital and Masaryk University, Brno, Czech Republic (J.S.) the University of Leicester, Glenfield General Hospital, Leicester (I.S.), the University of Glasgow, Glasgow (N.S.), the London School of Hygiene and Tropical Medicine (S.J.P.), and Imperial College, London (M.P.) - all in the United Kingdom Kyushu University, Fukuoka, Japan (H.T.) the University of Medicine and Pharmacy, Carol Davila University and Emergency Hospital, Bucharest, Romania (D.V.) the Heart Failure Center, Fuwai Hospital, Chinese Academy of Medical Science and Peking Union Medical College, Beijing (J.Z.) the Veterans Affairs Medical Center, Washington, DC (P.C.) National Heart Centre Singapore, Duke-National University of Singapore, Singapore (C.S.P.L.) Boehringer Ingelheim Pharmaceuticals, Ridgefield, CT (J.M.S.) and Baylor Heart and Vascular Institute, Dallas (M.P.)
Bocchi, Edimar
Autor Bocchi, Edimar From the Department of Cardiology (CVK) and the Berlin Institute of Health Center for Regenerative Therapies (BCRT), German Center for Cardiovascular Research (DZHK) partner site Berlin, Charité Universitätsmedizin Berlin, Berlin (S.D.A.), Universitätsklinikum des Saarlandes, Homberg (M. Böhm), RWTH Aachen University, Aachen (N.M.), Boehringer Ingelheim Pharma, Biberach (C.Z., S.S.), Boehringer Ingelheim International, Ingelheim (W.J., M. Brueckmann), and the Faculty of Medicine Mannheim, University of Heidelberg, Mannheim (M. Brueckmann) - all in Germany the University of Mississippi Medical Center, Jackson (J.B.) National and Kapodistrian University of Athens School of Medicine, Athens (G.F.) Université de Lorraine, INSERM, Centre d'Investigations Cliniques Plurithématique 1433, and INSERM Unité 1116, CHRU, F-CRIN INI-CRCT (Cardiovascular and Renal Clinical Trialists) (J.P.F.), and Université de Lorraine, INSERM INI-CRCT, CHRU (F.Z.) - both in Nancy, France the Cardiovascular Research and Development Center, Department of Surgery and Physiology, Faculty of Medicine of the University of Porto, Porto, Portugal (J.P.F.) Unidade de Insuficiência Cardíaca, Instituto do Coracao, Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de São Paulo, São Paulo (E.B.) Maastricht University Medical Center and the School for Cardiovascular Disease CARIM - both in Maastricht, the Netherlands (H.-P.B.-L.R.) the Department of Medicine, Seoul National University Bundang Hospital, Seoul, South Korea (D.-J.C.) Max Superspeciality Hospital, Saket, New Delhi, India (V.C.) the National Institute of Cardiology, Mexico City (E.C.-V.) McGill University Health Centre, Montreal (N.G.), and St. Michael's Hospital, University of Toronto, Toronto (S.V.) - both in Canada the Cardiology Service, Fundación Valle del Lili, Universidad Icesi, Cali, Colombia (J.E.G.-M.) the Department of Cardiovascular Diseases, University Hospitals Leuven, Leuven, Belgium (S.J.) Massachusetts General Hospital and Baim Institute for Clinical Research, Boston (J.L.J.) University Hospital, Santiago de Compostela, Spain (J.R.G.-J.) Heart and Vascular Center, Semmelweiss University, Budapest, Hungary (B.M.) Victorian Heart Institute, Monash University, Melbourne, VIC, Australia (S.J.N.) Argentine Catholic University, and Medical Advisor in Heart Failure, Pulmonary Hypertension and Intrathoracic Transplant at FLENI and IADT Institute - both in Buenos Aires (S.V.P.) Central Michigan University, Mount Pleasant (I.L.P.) Wroclaw Medical University, Wroclaw, Poland (P.P.) the Cardiovascular Department, Cardiology Division, Papa Giovanni XXIII Hospital, Bergamo (M.S.), and Università di Pisa, Pisa (S.T.) - both in Italy National Heart Centre Singapore, Singapore (D.S.) the Internal Cardiology Department, St. Ann University Hospital and Masaryk University, Brno, Czech Republic (J.S.) the University of Leicester, Glenfield General Hospital, Leicester (I.S.), the University of Glasgow, Glasgow (N.S.), the London School of Hygiene and Tropical Medicine (S.J.P.), and Imperial College, London (M.P.) - all in the United Kingdom Kyushu University, Fukuoka, Japan (H.T.) the University of Medicine and Pharmacy, Carol Davila University and Emergency Hospital, Bucharest, Romania (D.V.) the Heart Failure Center, Fuwai Hospital, Chinese Academy of Medical Science and Peking Union Medical College, Beijing (J.Z.) the Veterans Affairs Medical Center, Washington, DC (P.C.) National Heart Centre Singapore, Duke-National University of Singapore, Singapore (C.S.P.L.) Boehringer Ingelheim Pharmaceuticals, Ridgefield, CT (J.M.S.) and Baylor Heart and Vascular Institute, Dallas (M.P.)
Böhm, Michael
Autor Böhm, Michael From the Department of Cardiology (CVK) and the Berlin Institute of Health Center for Regenerative Therapies (BCRT), German Center for Cardiovascular Research (DZHK) partner site Berlin, Charité Universitätsmedizin Berlin, Berlin (S.D.A.), Universitätsklinikum des Saarlandes, Homberg (M. Böhm), RWTH Aachen University, Aachen (N.M.), Boehringer Ingelheim Pharma, Biberach (C.Z., S.S.), Boehringer Ingelheim International, Ingelheim (W.J., M. Brueckmann), and the Faculty of Medicine Mannheim, University of Heidelberg, Mannheim (M. Brueckmann) - all in Germany the University of Mississippi Medical Center, Jackson (J.B.) National and Kapodistrian University of Athens School of Medicine, Athens (G.F.) Université de Lorraine, INSERM, Centre d'Investigations Cliniques Plurithématique 1433, and INSERM Unité 1116, CHRU, F-CRIN INI-CRCT (Cardiovascular and Renal Clinical Trialists) (J.P.F.), and Université de Lorraine, INSERM INI-CRCT, CHRU (F.Z.) - both in Nancy, France the Cardiovascular Research and Development Center, Department of Surgery and Physiology, Faculty of Medicine of the University of Porto, Porto, Portugal (J.P.F.) Unidade de Insuficiência Cardíaca, Instituto do Coracao, Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de São Paulo, São Paulo (E.B.) Maastricht University Medical Center and the School for Cardiovascular Disease CARIM - both in Maastricht, the Netherlands (H.-P.B.-L.R.) the Department of Medicine, Seoul National University Bundang Hospital, Seoul, South Korea (D.-J.C.) Max Superspeciality Hospital, Saket, New Delhi, India (V.C.) the National Institute of Cardiology, Mexico City (E.C.-V.) McGill University Health Centre, Montreal (N.G.), and St. Michael's Hospital, University of Toronto, Toronto (S.V.) - both in Canada the Cardiology Service, Fundación Valle del Lili, Universidad Icesi, Cali, Colombia (J.E.G.-M.) the Department of Cardiovascular Diseases, University Hospitals Leuven, Leuven, Belgium (S.J.) Massachusetts General Hospital and Baim Institute for Clinical Research, Boston (J.L.J.) University Hospital, Santiago de Compostela, Spain (J.R.G.-J.) Heart and Vascular Center, Semmelweiss University, Budapest, Hungary (B.M.) Victorian Heart Institute, Monash University, Melbourne, VIC, Australia (S.J.N.) Argentine Catholic University, and Medical Advisor in Heart Failure, Pulmonary Hypertension and Intrathoracic Transplant at FLENI and IADT Institute - both in Buenos Aires (S.V.P.) Central Michigan University, Mount Pleasant (I.L.P.) Wroclaw Medical University, Wroclaw, Poland (P.P.) the Cardiovascular Department, Cardiology Division, Papa Giovanni XXIII Hospital, Bergamo (M.S.), and Università di Pisa, Pisa (S.T.) - both in Italy National Heart Centre Singapore, Singapore (D.S.) the Internal Cardiology Department, St. Ann University Hospital and Masaryk University, Brno, Czech Republic (J.S.) the University of Leicester, Glenfield General Hospital, Leicester (I.S.), the University of Glasgow, Glasgow (N.S.), the London School of Hygiene and Tropical Medicine (S.J.P.), and Imperial College, London (M.P.) - all in the United Kingdom Kyushu University, Fukuoka, Japan (H.T.) the University of Medicine and Pharmacy, Carol Davila University and Emergency Hospital, Bucharest, Romania (D.V.) the Heart Failure Center, Fuwai Hospital, Chinese Academy of Medical Science and Peking Union Medical College, Beijing (J.Z.) the Veterans Affairs Medical Center, Washington, DC (P.C.) National Heart Centre Singapore, Duke-National University of Singapore, Singapore (C.S.P.L.) Boehringer Ingelheim Pharmaceuticals, Ridgefield, CT (J.M.S.) and Baylor Heart and Vascular Institute, Dallas (M.P.)
Brunner-La Rocca, Hans-Peter
Autor Brunner-La Rocca, Hans-Peter From the Department of Cardiology (CVK) and the Berlin Institute of Health Center for Regenerative Therapies (BCRT), German Center for Cardiovascular Research (DZHK) partner site Berlin, Charité Universitätsmedizin Berlin, Berlin (S.D.A.), Universitätsklinikum des Saarlandes, Homberg (M. Böhm), RWTH Aachen University, Aachen (N.M.), Boehringer Ingelheim Pharma, Biberach (C.Z., S.S.), Boehringer Ingelheim International, Ingelheim (W.J., M. Brueckmann), and the Faculty of Medicine Mannheim, University of Heidelberg, Mannheim (M. Brueckmann) - all in Germany the University of Mississippi Medical Center, Jackson (J.B.) National and Kapodistrian University of Athens School of Medicine, Athens (G.F.) Université de Lorraine, INSERM, Centre d'Investigations Cliniques Plurithématique 1433, and INSERM Unité 1116, CHRU, F-CRIN INI-CRCT (Cardiovascular and Renal Clinical Trialists) (J.P.F.), and Université de Lorraine, INSERM INI-CRCT, CHRU (F.Z.) - both in Nancy, France the Cardiovascular Research and Development Center, Department of Surgery and Physiology, Faculty of Medicine of the University of Porto, Porto, Portugal (J.P.F.) Unidade de Insuficiência Cardíaca, Instituto do Coracao, Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de São Paulo, São Paulo (E.B.) Maastricht University Medical Center and the School for Cardiovascular Disease CARIM - both in Maastricht, the Netherlands (H.-P.B.-L.R.) the Department of Medicine, Seoul National University Bundang Hospital, Seoul, South Korea (D.-J.C.) Max Superspeciality Hospital, Saket, New Delhi, India (V.C.) the National Institute of Cardiology, Mexico City (E.C.-V.) McGill University Health Centre, Montreal (N.G.), and St. Michael's Hospital, University of Toronto, Toronto (S.V.) - both in Canada the Cardiology Service, Fundación Valle del Lili, Universidad Icesi, Cali, Colombia (J.E.G.-M.) the Department of Cardiovascular Diseases, University Hospitals Leuven, Leuven, Belgium (S.J.) Massachusetts General Hospital and Baim Institute for Clinical Research, Boston (J.L.J.) University Hospital, Santiago de Compostela, Spain (J.R.G.-J.) Heart and Vascular Center, Semmelweiss University, Budapest, Hungary (B.M.) Victorian Heart Institute, Monash University, Melbourne, VIC, Australia (S.J.N.) Argentine Catholic University, and Medical Advisor in Heart Failure, Pulmonary Hypertension and Intrathoracic Transplant at FLENI and IADT Institute - both in Buenos Aires (S.V.P.) Central Michigan University, Mount Pleasant (I.L.P.) Wroclaw Medical University, Wroclaw, Poland (P.P.) the Cardiovascular Department, Cardiology Division, Papa Giovanni XXIII Hospital, Bergamo (M.S.), and Università di Pisa, Pisa (S.T.) - both in Italy National Heart Centre Singapore, Singapore (D.S.) the Internal Cardiology Department, St. Ann University Hospital and Masaryk University, Brno, Czech Republic (J.S.) the University of Leicester, Glenfield General Hospital, Leicester (I.S.), the University of Glasgow, Glasgow (N.S.), the London School of Hygiene and Tropical Medicine (S.J.P.), and Imperial College, London (M.P.) - all in the United Kingdom Kyushu University, Fukuoka, Japan (H.T.) the University of Medicine and Pharmacy, Carol Davila University and Emergency Hospital, Bucharest, Romania (D.V.) the Heart Failure Center, Fuwai Hospital, Chinese Academy of Medical Science and Peking Union Medical College, Beijing (J.Z.) the Veterans Affairs Medical Center, Washington, DC (P.C.) National Heart Centre Singapore, Duke-National University of Singapore, Singapore (C.S.P.L.) Boehringer Ingelheim Pharmaceuticals, Ridgefield, CT (J.M.S.) and Baylor Heart and Vascular Institute, Dallas (M.P.)
Choi, Dong-Ju
Autor Choi, Dong-Ju From the Department of Cardiology (CVK) and the Berlin Institute of Health Center for Regenerative Therapies (BCRT), German Center for Cardiovascular Research (DZHK) partner site Berlin, Charité Universitätsmedizin Berlin, Berlin (S.D.A.), Universitätsklinikum des Saarlandes, Homberg (M. Böhm), RWTH Aachen University, Aachen (N.M.), Boehringer Ingelheim Pharma, Biberach (C.Z., S.S.), Boehringer Ingelheim International, Ingelheim (W.J., M. Brueckmann), and the Faculty of Medicine Mannheim, University of Heidelberg, Mannheim (M. Brueckmann) - all in Germany the University of Mississippi Medical Center, Jackson (J.B.) National and Kapodistrian University of Athens School of Medicine, Athens (G.F.) Université de Lorraine, INSERM, Centre d'Investigations Cliniques Plurithématique 1433, and INSERM Unité 1116, CHRU, F-CRIN INI-CRCT (Cardiovascular and Renal Clinical Trialists) (J.P.F.), and Université de Lorraine, INSERM INI-CRCT, CHRU (F.Z.) - both in Nancy, France the Cardiovascular Research and Development Center, Department of Surgery and Physiology, Faculty of Medicine of the University of Porto, Porto, Portugal (J.P.F.) Unidade de Insuficiência Cardíaca, Instituto do Coracao, Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de São Paulo, São Paulo (E.B.) Maastricht University Medical Center and the School for Cardiovascular Disease CARIM - both in Maastricht, the Netherlands (H.-P.B.-L.R.) the Department of Medicine, Seoul National University Bundang Hospital, Seoul, South Korea (D.-J.C.) Max Superspeciality Hospital, Saket, New Delhi, India (V.C.) the National Institute of Cardiology, Mexico City (E.C.-V.) McGill University Health Centre, Montreal (N.G.), and St. Michael's Hospital, University of Toronto, Toronto (S.V.) - both in Canada the Cardiology Service, Fundación Valle del Lili, Universidad Icesi, Cali, Colombia (J.E.G.-M.) the Department of Cardiovascular Diseases, University Hospitals Leuven, Leuven, Belgium (S.J.) Massachusetts General Hospital and Baim Institute for Clinical Research, Boston (J.L.J.) University Hospital, Santiago de Compostela, Spain (J.R.G.-J.) Heart and Vascular Center, Semmelweiss University, Budapest, Hungary (B.M.) Victorian Heart Institute, Monash University, Melbourne, VIC, Australia (S.J.N.) Argentine Catholic University, and Medical Advisor in Heart Failure, Pulmonary Hypertension and Intrathoracic Transplant at FLENI and IADT Institute - both in Buenos Aires (S.V.P.) Central Michigan University, Mount Pleasant (I.L.P.) Wroclaw Medical University, Wroclaw, Poland (P.P.) the Cardiovascular Department, Cardiology Division, Papa Giovanni XXIII Hospital, Bergamo (M.S.), and Università di Pisa, Pisa (S.T.) - both in Italy National Heart Centre Singapore, Singapore (D.S.) the Internal Cardiology Department, St. Ann University Hospital and Masaryk University, Brno, Czech Republic (J.S.) the University of Leicester, Glenfield General Hospital, Leicester (I.S.), the University of Glasgow, Glasgow (N.S.), the London School of Hygiene and Tropical Medicine (S.J.P.), and Imperial College, London (M.P.) - all in the United Kingdom Kyushu University, Fukuoka, Japan (H.T.) the University of Medicine and Pharmacy, Carol Davila University and Emergency Hospital, Bucharest, Romania (D.V.) the Heart Failure Center, Fuwai Hospital, Chinese Academy of Medical Science and Peking Union Medical College, Beijing (J.Z.) the Veterans Affairs Medical Center, Washington, DC (P.C.) National Heart Centre Singapore, Duke-National University of Singapore, Singapore (C.S.P.L.) Boehringer Ingelheim Pharmaceuticals, Ridgefield, CT (J.M.S.) and Baylor Heart and Vascular Institute, Dallas (M.P.)
Chopra, Vijay
Autor Chopra, Vijay From the Department of Cardiology (CVK) and the Berlin Institute of Health Center for Regenerative Therapies (BCRT), German Center for Cardiovascular Research (DZHK) partner site Berlin, Charité Universitätsmedizin Berlin, Berlin (S.D.A.), Universitätsklinikum des Saarlandes, Homberg (M. Böhm), RWTH Aachen University, Aachen (N.M.), Boehringer Ingelheim Pharma, Biberach (C.Z., S.S.), Boehringer Ingelheim International, Ingelheim (W.J., M. Brueckmann), and the Faculty of Medicine Mannheim, University of Heidelberg, Mannheim (M. Brueckmann) - all in Germany the University of Mississippi Medical Center, Jackson (J.B.) National and Kapodistrian University of Athens School of Medicine, Athens (G.F.) Université de Lorraine, INSERM, Centre d'Investigations Cliniques Plurithématique 1433, and INSERM Unité 1116, CHRU, F-CRIN INI-CRCT (Cardiovascular and Renal Clinical Trialists) (J.P.F.), and Université de Lorraine, INSERM INI-CRCT, CHRU (F.Z.) - both in Nancy, France the Cardiovascular Research and Development Center, Department of Surgery and Physiology, Faculty of Medicine of the University of Porto, Porto, Portugal (J.P.F.) Unidade de Insuficiência Cardíaca, Instituto do Coracao, Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de São Paulo, São Paulo (E.B.) Maastricht University Medical Center and the School for Cardiovascular Disease CARIM - both in Maastricht, the Netherlands (H.-P.B.-L.R.) the Department of Medicine, Seoul National University Bundang Hospital, Seoul, South Korea (D.-J.C.) Max Superspeciality Hospital, Saket, New Delhi, India (V.C.) the National Institute of Cardiology, Mexico City (E.C.-V.) McGill University Health Centre, Montreal (N.G.), and St. Michael's Hospital, University of Toronto, Toronto (S.V.) - both in Canada the Cardiology Service, Fundación Valle del Lili, Universidad Icesi, Cali, Colombia (J.E.G.-M.) the Department of Cardiovascular Diseases, University Hospitals Leuven, Leuven, Belgium (S.J.) Massachusetts General Hospital and Baim Institute for Clinical Research, Boston (J.L.J.) University Hospital, Santiago de Compostela, Spain (J.R.G.-J.) Heart and Vascular Center, Semmelweiss University, Budapest, Hungary (B.M.) Victorian Heart Institute, Monash University, Melbourne, VIC, Australia (S.J.N.) Argentine Catholic University, and Medical Advisor in Heart Failure, Pulmonary Hypertension and Intrathoracic Transplant at FLENI and IADT Institute - both in Buenos Aires (S.V.P.) Central Michigan University, Mount Pleasant (I.L.P.) Wroclaw Medical University, Wroclaw, Poland (P.P.) the Cardiovascular Department, Cardiology Division, Papa Giovanni XXIII Hospital, Bergamo (M.S.), and Università di Pisa, Pisa (S.T.) - both in Italy National Heart Centre Singapore, Singapore (D.S.) the Internal Cardiology Department, St. Ann University Hospital and Masaryk University, Brno, Czech Republic (J.S.) the University of Leicester, Glenfield General Hospital, Leicester (I.S.), the University of Glasgow, Glasgow (N.S.), the London School of Hygiene and Tropical Medicine (S.J.P.), and Imperial College, London (M.P.) - all in the United Kingdom Kyushu University, Fukuoka, Japan (H.T.) the University of Medicine and Pharmacy, Carol Davila University and Emergency Hospital, Bucharest, Romania (D.V.) the Heart Failure Center, Fuwai Hospital, Chinese Academy of Medical Science and Peking Union Medical College, Beijing (J.Z.) the Veterans Affairs Medical Center, Washington, DC (P.C.) National Heart Centre Singapore, Duke-National University of Singapore, Singapore (C.S.P.L.) Boehringer Ingelheim Pharmaceuticals, Ridgefield, CT (J.M.S.) and Baylor Heart and Vascular Institute, Dallas (M.P.)
Chuquiure-Valenzuela, Eduardo
Autor Chuquiure-Valenzuela, Eduardo From the Department of Cardiology (CVK) and the Berlin Institute of Health Center for Regenerative Therapies (BCRT), German Center for Cardiovascular Research (DZHK) partner site Berlin, Charité Universitätsmedizin Berlin, Berlin (S.D.A.), Universitätsklinikum des Saarlandes, Homberg (M. Böhm), RWTH Aachen University, Aachen (N.M.), Boehringer Ingelheim Pharma, Biberach (C.Z., S.S.), Boehringer Ingelheim International, Ingelheim (W.J., M. Brueckmann), and the Faculty of Medicine Mannheim, University of Heidelberg, Mannheim (M. Brueckmann) - all in Germany the University of Mississippi Medical Center, Jackson (J.B.) National and Kapodistrian University of Athens School of Medicine, Athens (G.F.) Université de Lorraine, INSERM, Centre d'Investigations Cliniques Plurithématique 1433, and INSERM Unité 1116, CHRU, F-CRIN INI-CRCT (Cardiovascular and Renal Clinical Trialists) (J.P.F.), and Université de Lorraine, INSERM INI-CRCT, CHRU (F.Z.) - both in Nancy, France the Cardiovascular Research and Development Center, Department of Surgery and Physiology, Faculty of Medicine of the University of Porto, Porto, Portugal (J.P.F.) Unidade de Insuficiência Cardíaca, Instituto do Coracao, Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de São Paulo, São Paulo (E.B.) Maastricht University Medical Center and the School for Cardiovascular Disease CARIM - both in Maastricht, the Netherlands (H.-P.B.-L.R.) the Department of Medicine, Seoul National University Bundang Hospital, Seoul, South Korea (D.-J.C.) Max Superspeciality Hospital, Saket, New Delhi, India (V.C.) the National Institute of Cardiology, Mexico City (E.C.-V.) McGill University Health Centre, Montreal (N.G.), and St. Michael's Hospital, University of Toronto, Toronto (S.V.) - both in Canada the Cardiology Service, Fundación Valle del Lili, Universidad Icesi, Cali, Colombia (J.E.G.-M.) the Department of Cardiovascular Diseases, University Hospitals Leuven, Leuven, Belgium (S.J.) Massachusetts General Hospital and Baim Institute for Clinical Research, Boston (J.L.J.) University Hospital, Santiago de Compostela, Spain (J.R.G.-J.) Heart and Vascular Center, Semmelweiss University, Budapest, Hungary (B.M.) Victorian Heart Institute, Monash University, Melbourne, VIC, Australia (S.J.N.) Argentine Catholic University, and Medical Advisor in Heart Failure, Pulmonary Hypertension and Intrathoracic Transplant at FLENI and IADT Institute - both in Buenos Aires (S.V.P.) Central Michigan University, Mount Pleasant (I.L.P.) Wroclaw Medical University, Wroclaw, Poland (P.P.) the Cardiovascular Department, Cardiology Division, Papa Giovanni XXIII Hospital, Bergamo (M.S.), and Università di Pisa, Pisa (S.T.) - both in Italy National Heart Centre Singapore, Singapore (D.S.) the Internal Cardiology Department, St. Ann University Hospital and Masaryk University, Brno, Czech Republic (J.S.) the University of Leicester, Glenfield General Hospital, Leicester (I.S.), the University of Glasgow, Glasgow (N.S.), the London School of Hygiene and Tropical Medicine (S.J.P.), and Imperial College, London (M.P.) - all in the United Kingdom Kyushu University, Fukuoka, Japan (H.T.) the University of Medicine and Pharmacy, Carol Davila University and Emergency Hospital, Bucharest, Romania (D.V.) the Heart Failure Center, Fuwai Hospital, Chinese Academy of Medical Science and Peking Union Medical College, Beijing (J.Z.) the Veterans Affairs Medical Center, Washington, DC (P.C.) National Heart Centre Singapore, Duke-National University of Singapore, Singapore (C.S.P.L.) Boehringer Ingelheim Pharmaceuticals, Ridgefield, CT (J.M.S.) and Baylor Heart and Vascular Institute, Dallas (M.P.)

The New England journal of medicine. 2021 ; 385 (16) : 1451-1461. [pub] 20210827

N Engl J Med
ISSN 1533-4406
Medvik
Zdroj

BACKGROUND: Sodium-glucose cotransporter 2 inhibitors reduce the risk of hospitalization for heart failure in patients with heart failure and a reduced ejection fraction, but their effects in patients with heart failure and a preserved ejection fraction are uncertain. METHODS: In this double-blind trial, we randomly assigned 5988 patients with class II-IV heart failure and an ejection fraction of more than 40% to receive empagliflozin (10 mg once daily) or placebo, in addition to usual therapy. The primary outcome was a composite of cardiovascular death or hospitalization for heart failure. RESULTS: Over a median of 26.2 months, a primary outcome event occurred in 415 of 2997 patients (13.8%) in the empagliflozin group and in 511 of 2991 patients (17.1%) in the placebo group (hazard ratio, 0.79; 95% confidence interval [CI], 0.69 to 0.90; P<0.001). This effect was mainly related to a lower risk of hospitalization for heart failure in the empagliflozin group. The effects of empagliflozin appeared consistent in patients with or without diabetes. The total number of hospitalizations for heart failure was lower in the empagliflozin group than in the placebo group (407 with empagliflozin and 541 with placebo; hazard ratio, 0.73; 95% CI, 0.61 to 0.88; P<0.001). Uncomplicated genital and urinary tract infections and hypotension were reported more frequently with empagliflozin. CONCLUSIONS: Empagliflozin reduced the combined risk of cardiovascular death or hospitalization for heart failure in patients with heart failure and a preserved ejection fraction, regardless of the presence or absence of diabetes. (Funded by Boehringer Ingelheim and Eli Lilly; EMPEROR-Preserved ClinicalTrials.gov number, NCT03057951).

Článek

Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure

The New England journal of medicine. 2020 ; 383 (15) : 1413-1424. [pub] 20200828

N Engl J Med
ISSN 1533-4406
Medvik
Zdroj

BACKGROUND: Sodium-glucose cotransporter 2 (SGLT2) inhibitors reduce the risk of hospitalization for heart failure in patients regardless of the presence or absence of diabetes. More evidence is needed regarding the effects of these drugs in patients across the broad spectrum of heart failure, including those with a markedly reduced ejection fraction. METHODS: In this double-blind trial, we randomly assigned 3730 patients with class II, III, or IV heart failure and an ejection fraction of 40% or less to receive empagliflozin (10 mg once daily) or placebo, in addition to recommended therapy. The primary outcome was a composite of cardiovascular death or hospitalization for worsening heart failure. RESULTS: During a median of 16 months, a primary outcome event occurred in 361 of 1863 patients (19.4%) in the empagliflozin group and in 462 of 1867 patients (24.7%) in the placebo group (hazard ratio for cardiovascular death or hospitalization for heart failure, 0.75; 95% confidence interval [CI], 0.65 to 0.86; P<0.001). The effect of empagliflozin on the primary outcome was consistent in patients regardless of the presence or absence of diabetes. The total number of hospitalizations for heart failure was lower in the empagliflozin group than in the placebo group (hazard ratio, 0.70; 95% CI, 0.58 to 0.85; P<0.001). The annual rate of decline in the estimated glomerular filtration rate was slower in the empagliflozin group than in the placebo group (-0.55 vs. -2.28 ml per minute per 1.73 m2 of body-surface area per year, P<0.001), and empagliflozin-treated patients had a lower risk of serious renal outcomes. Uncomplicated genital tract infection was reported more frequently with empagliflozin. CONCLUSIONS: Among patients receiving recommended therapy for heart failure, those in the empagliflozin group had a lower risk of cardiovascular death or hospitalization for heart failure than those in the placebo group, regardless of the presence or absence of diabetes. (Funded by Boehringer Ingelheim and Eli Lilly; EMPEROR-Reduced ClinicalTrials.gov number, NCT03057977.).

Článek

Challenges in personalised management of chronic diseases-heart failure as prominent example to advance the care process

The EPMA journal. 2016 ; 7 (1) : 2. [pub] 2015

EPMA J
ISSN 1878-5077
Medvik
Zdroj

Chronic diseases are the leading causes of morbidity and mortality in Europe, accounting for more than 2/3 of all death causes and 75 % of the healthcare costs. Heart failure is one of the most prominent, prevalent and complex chronic conditions and is accompanied with multiple other chronic diseases. The current approach to care has important shortcomings with respect to diagnosis, treatment and care processes. A critical aspect of this situation is that interaction between stakeholders is limited and chronic diseases are usually addressed in isolation. Health care in Western countries requires an innovative approach to address chronic diseases to provide sustainability of care and to limit the excessive costs that may threaten the current systems. The increasing prevalence of chronic diseases combined with their enormous economic impact and the increasing shortage of healthcare providers are among the most critical threats. Attempts to solve these problems have failed, and future limitations in financial resources will result in much lower quality of care. Thus, changing the approach to care for chronic diseases is of utmost social importance.

Kolekce

Publikováno

Filtry

Filtry

* Zobrazit nápovědu

* Zobrazit nápovědu

Upřesnit dle MeSH